Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
NCT07218783Phase 3Recruiting
- Lead sponsor
- SpyGlass Pharma, Inc. (Industry)
- Enrollment
- 400 (estimated)
- Start date
- 15 Oct 2025
- Primary completion
- 31 Mar 2029 (estimated)
- Study completion
- 31 Mar 2031
- Last update posted
- 20 Oct 2025
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 2
Interventions
- Bimatoprost Implant System Drug
- SpyGlass IOL Device
- Timolol Maleate Ophthalmic Solution, 0.5% Drug
- Commercial IOL Device
Conditions and primary outcome
- Cataract
- Glaucoma
- Ocular Hypertension
Primary outcome
Mean IOP Reduction from Baseline (mmHg) (Weeks 2 and 6, and Month 3); BCDVA 20/40 or better (Month 6)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07218783.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07218783 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.